The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: Preclinical and clinical data;Die Bedeutung des glutamatergen Systems farmakotherapie der Depression: präklinische und klinische Daten

Fortschritte der Neurologie Psychiatrie

Volumn 79, Issue 4, 2011, Pages 204-212

  Paslakis, G ^a   Gass, P ^a   Deuschle, M ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

depression; glia cells; glutamate; ketamine; NMDA receptor

Indexed keywords

GLUTAMIC ACID;

ARTICLE; DEPRESSION; HUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; KETAMINE; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; RILUZOLE; STRESS, PSYCHOLOGICAL;

EID: 79954421027     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0029-1245770     Document Type: Article

References (121)

1. Ustün T B., Ayuso-Mateos J L., Chatterji S et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004 184 386-392 (Pubitemid 38624764)
2. Paykel E S., Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005 15 411-423 (Pubitemid 40943545)
3. Kessler R C., Chiu W T., Demler O et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 62 617-627 (Pubitemid 40973437)
4. Trivedi M H., Rush A J., Wisniewski S R. et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D. Implications for clinical practice. Am J Psychiatry 2006 163 28-40 (Pubitemid 43050100)
5. Thase M E. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004 9 808-821 (Pubitemid 39602937)
6. DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol 2006 20 11-18
7. Fava M, Rush A J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006 75 139-153
8. Frieling H, Hillemacher T, Demling J H. et al. New options in the treatment of depression. Fortschr Neurol Psychiatr 2007 75 641-652 Review. German (Pubitemid 350205647)
9. Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectrom 2005 10 808-819 (Pubitemid 41531934)
10. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009 61 105-123
11. Pittenger C, Sanacora G, Krystal J H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007 6 101-115 (Pubitemid 46681771)
12. Rajkowska G, Miguel-Hidalgo J J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007 6 219-233 (Pubitemid 46916253)
13. Mao L, Tang Q et al. Regulation of MAPK/ERK phosphorylation via ionotropic glutamate receptors in cultured rat striatal neurons. Eur J Neurosci 2004 19 1207-1216 (Pubitemid 38387198)
14. Mao L, Yang L et al. Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons. J Biol Chem 2005 280 12602-12610
15. Riccio A, Ginty D D. What a privilege to reside at the synapse: NMDA receptor signaling to CREB. Nature Neuroscience 2002 5 389-390 (Pubitemid 34454237)
16. Chourbaji S, Brandwein C, Gass P. Altering BDNF expression by genetics and/or environment: Impact for emotional and depression-like behaviour in laboratory mice. Neurosci Biobehav Rev 17 Jul 2010 [Epub ahead of print]
17. Gass P, Hellweg R. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders? Int J Neuropsychopharmacol 2010 Epub 2009 Dec 9 13 1-4
18. Hellweg R, Ziegenhorn A, Heuser I et al. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008 41 66-71 (Pubitemid 351427525)
19. Hardingham G E., Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002 5 405-414 (Pubitemid 34454245)
20. Ivanov A, Pellegrino C, Rama S et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol 2006 572 789-798
21. Hardingham G E., Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002 5 405-414 (Pubitemid 34454245)
22. Kim J S., Schmid-Burgk W, Claus D et al. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982 232 299-304 (Pubitemid 13124834)
23. Altamura C A., Mauri M C., Ferrara A et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993 150 1713-1731
24. Mitani H, Shirayama Y, Yamada T et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006 30 1155-1158 (Pubitemid 43928219)
25. Levine J, Panchalingam K, Rapoport A et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000 47 586-593 (Pubitemid 30169251)
26. Maes M, Verkerk R, Vandoolaeghe E et al. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998 97 302-308 (Pubitemid 28179268)
27. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007 62 1310-1316 (Pubitemid 350060893)
28. Francis P T., Poynton A, Lowe S L. et al. Brain amino acid concentrations and Ca2 + -dependent release in intractable depression assessed antemortem. Brain Res 1989 494 315-324 (Pubitemid 19194545)
29. Law A J., Deakin J F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport 2001 12 2971-2974 (Pubitemid 32882018)
30. Nudmamud-Thanoi S, Reynolds G P. The NR 1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 2004 372 173-177 (Pubitemid 39505251)
31. Beneyto M, Kristiansen L V., Oni-Orisan A et al. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007 32 1888-1902 (Pubitemid 47258508)
32. Feyissa A M., Chandran A, Stockmeier C A. et al. Reduced levels of NR 2A and NR 2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009 33 70-75
33. Karolewicz B, Feyissa A M., Chandran A et al. Glutamate receptors expression in postmortem brain from depressed subjects. Biol Psychiatry 2009 65 177
34. Hasler G. Abnormal prefrontal glutamatergic and GABAeric systems in mood and anxiety disorders. Biol Psychiatry 2009 65 176-177
35. Karolewicz B, Stockmeier C A., Ordway G A. et al. Elevated levels of the NR 2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacol 2005 30 1557-1567 (Pubitemid 41153128)
36. Meador-Woodruff J H., Hogg Jr A J., Smith R E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 2001 55 631-640 (Pubitemid 32888382)
37. Choudary P V., Molnar M, Evans S J. et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005 102 15653-15658 (Pubitemid 41528111)
38. Sanacora G, Gueorguieva R, Epperson C N. et al. Subtype-specific alterations of -aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004 61 705-713 (Pubitemid 38890805)
39. Auer D P., Putz B, Kraft E et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000 47 305-313 (Pubitemid 30109243)
40. Ajilore O, Haroon E, Kumaran S et al. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology 2007 32 1224-1231 (Pubitemid 46788852)
41. Hasler G, Veen J W., Tumonis T van der et al. Reduced prefrontal glutamate/glutamine and -aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007 64 193-200 (Pubitemid 46220776)
42. Block W, Träber F, Widdern O von et al. Proton MR spectroscopy of the hippocampus at 3T in patients with unipolar major depressive disorder: correlates and predictors of treatment responses. Int J Neuropsychopharmacol 2009 12 415-422
43. Kendler K S., Kuhn J, Prescott C A. The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am J Psychiatry 2004 161 631-636 (Pubitemid 38445506)
44. Sapolsky R M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000 48 755-765
45. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 2002 51 775-787 (Pubitemid 34451064)
46. Bagley J, Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 1997 77 65-73 (Pubitemid 27060307)
47. Banasr M, Valentine G W., Li X Y. et al. Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry 2007 62 496-504 (Pubitemid 47284039)
48. Czeh B, Lucassen P J. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci 2007 257 250-60 (Pubitemid 47301403)
49. Czeh B, Muller-Keuker J I., Rygula R et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 2007 32 1490-1503 (Pubitemid 46920152)
50. Nowak G, Trullas R, Layer R T. et al. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993 265 1380-1386 (Pubitemid 23321045)
51. Nowak G, Li Y, Paul I A. Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. Eur J Pharmacol 1996 295 75-85 (Pubitemid 26027124)
52. Nowak G, Legutko B, Skolnick P et al. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur J Pharmacol 1998 342 367-370 (Pubitemid 28149993)
53. Paul I A., Nowak G, Layer R T. et al. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994 269 95-102 (Pubitemid 24143240)
54. Skolnick P, Layer R T., Popik P et al. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996 29 23-26 (Pubitemid 26072654)
55. Boyer P A., Skolnick P, Fossom L H. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. J Mol Neurosci 1998 10 219-233 (Pubitemid 28427889)
56. Michael-Titus A T., Bains S, Jeetle J et al. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 2000 100 681-684
57. Tokarski K, Bobula B, Wabno J et al. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 2008 153 789-795
58. Golembiowska K, Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol 2000 52 441-448 (Pubitemid 32045907)
59. Sernagor E, Kuhn D, Vyklicky Jr L et al. Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron 1989 2 1221-1227
60. Cai Z, McCaslin P P. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and Nmethyl- D-aspartate-induced intracellular Ca2 + levels in neuronal culture. Eur J Pharmacol 1992 219 53-57
61. Watanabe Y, Saito H, Abe K. Tricyclic antidepressants block NMDA receptor-mediated synaptic responses and induction of long-term potentiation in rat hippocampal slices. Neuropharmacology 1993 32 479-486 (Pubitemid 23161558)
62. Takebayashi M, Kagaya A, Inagaki M et al. Effects of antidepressants on gamma-aminobutyric acid- and N-methyl-D-aspartate-induced intracellular Ca(2 +) concentration increases in primary cultured rat cortical neurons. Neuropsychobiology 2000 42 120-126
63. Bonanno G, Giambelli R, Raiteri L et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005 25 3270-3279 (Pubitemid 40471335)
64. Szasz B K., Mike A, Karoly R et al. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol Psychiatry 2007 62 1303-1309 (Pubitemid 350060896)
65. Mayer A, Szasz B K., Kiss J P. Inhibitory effect of antidepressants on the NMDA-evoked ([3] H)noradrenaline release from rat hippocampal slices. Neurochem Int 2009 55 383-388
66. Svenningsson P, Tzavara E T., Witkin J M. et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 2002 99 3182-3187 (Pubitemid 34240606)
67. Svenningsson P, Bateup H, Qi H et al. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci 2007 26 3509-3517 (Pubitemid 350243523)
68. Du J, Suzuki K, Wei Y et al. The Anticonvulsants lamotrigine, riluzole and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007 32 793-802 (Pubitemid 46426179)
69. Martinez-Turrillas R, Frechilla D, De lRio J. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 2002 43 1230-1237 (Pubitemid 36090128)
70. Barbon A, Popoli M, La V ia L et al. Regulation of editing and expression of glutamate alpha-amino-propionic-acid [AMPA]/kainate receptors by antidepressant drugs. Biol Psychiatry 2006 59 713-720
71. Bobula B, Tokarski K, Hess G. Repeated administration of antidepressants decreases field potenzials in rat frontal cortex. Neuroscience 2003 120 765-769 (Pubitemid 36928073)
72. Bobula B, Hess G. Antidepressant treatments-induced modifications of glutamatergic transmission in rat frontal cortex. Pharmacol Rep 2008 60 865-871
73. Dixon J F., Hokin L E. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA 1998 95 8363-8368 (Pubitemid 28326118)
74. Greenhill S D., Jones R S. Diverse antiepileptic drugs increase the ratio of background synaptic inhibition to excitation and decrease neuronal excitability in neurones of the rat entorhinal cortex in vitro. Neuroscience 2010 167 456-474
75. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990 185 1-10 (Pubitemid 20254891)
76. Kos T, Legutko B, Danysz W et al. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. J Pharmacol Exp Ther 2006 318 1128-1136 (Pubitemid 44268318)
77. Chaturvedi H K., Bapna J S., Chandra D. Effect of fluvoxamine and N-methyl-Daspartate receptor antagonists on shock-induced depression in mice. Indian J Physiol Pharmacol 2001 45 199-207 (Pubitemid 32520041)
78. Yilmaz A, Schulz D, Aksoy A et al. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002 71 341-344
79. Maeng S, Zarate Jr C A., Du J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of &alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008 63 349-352 (Pubitemid 351146651)
80. Garcia L S., Comim C M., Valvassori S S. et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 2008 103 502-506
81. Garcia L S., Comim C M., Valvassori S S. et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008 32 140-144
82. Engin E, Treit D, Dickson C T. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009 161 359-369 Erratum in: Neuroscience 2009; 162: 1438 - 1439
83. Kos T, Popik P, Pietraszek M et al. Effect of 5-HT3 receptor antagonist MDL 72 222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol 2006 16 297-310
84. Maj J, Rogz Z. Synergistic effect of amantadine and imipramine in the forced swimming test. Pol J Pharmacol 2000 52 111-114 (Pubitemid 30311781)
85. Almeida R C., Souza D G., Soletti R C. et al. Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice. Neurosci Lett 2006 395 93-97 (Pubitemid 43188871)
86. Rogoz Z, Skuza G, Maj J et al. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002 42 1024-1030 (Pubitemid 34790257)
87. Banasr M, Chowdhury G M., Terwilliger R et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 30 Sep 2008 [Epub ahead of print]
88. Alt A, Witkin J M., Bleakman D. A role for AMPA receptors in mood disorders. Curr Pharm Des 2005 11 1511-1527
89. Bleakman D, Alt A, Witkin J M. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets 2007 6 117-126 (Pubitemid 46681772)
90. O'Neill M J., Witkin J M. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 2007 8 603-620 (Pubitemid 46794920)
91. Chourbaji S, Vogt M A., Fumagalli F et al. AMPA receptor subunit 1 [GluR-A] knockout mice model the glutamate hypothesis of depression. FASEB J 2008 22 3129-3134
92. Belozertseva V, Kos T, Popik P et al. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007 17 172-179 (Pubitemid 44779190)
93. Li X, Need A B., Baez M et al. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006 319 254-259 (Pubitemid 44455130)
94. Chaki S, Yoshikawa R, Hirota S et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004 46 457-467 (Pubitemid 38224431)
95. Bespalov A Y., Gaalen M M., Sukhotina I A. et al. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341 495, in animal models of anxiety and depression. Eur J Pharmacol 2008 592 96-102
96. Paucha A van, Tatarczyska E, Braski P et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004 46 151-159
97. Palucha A, Klak K, Branski P et al. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology 2007 194 555-562 (Pubitemid 47492987)
98. Cryan J F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005 4 775-790 (Pubitemid 43090498)
99. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch 1991 419 603-609
100. Zarate Jr C A., Payne J L., Quiroz J et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004 161 171-174 (Pubitemid 38419327)
101. Sanacora G, Kendell S F., Fenton L et al. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry 2004 161 2132
102. Zarate Jr C A., Quiroz J A., Singh J B. et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005 57 430-432 (Pubitemid 40215774)
103. Mathew S J., Amiel J M., Coplan J D. et al. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005 162 2379-2381 (Pubitemid 41740219)
104. Mathew S J., Murrough J W., aan het Rot M et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010 13 71-82
105. Ferguson J M., Shingleton R N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007 30 136-144 (Pubitemid 46871863)
106. Zarate Jr C A., Singh J B., Quiroz J A. et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006 163 153-155 (Pubitemid 43050119)
107. Muhonen L H., Lönnqvist J, Juva K et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008 69 392-399 (Pubitemid 351549391)
108. Berman R M., Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000 47 351-354 (Pubitemid 30109248)
109. Zarate Jr C A., Singh J B., Carlson P J. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006 63 856-864 (Pubitemid 44188478)
110. Paslakis G, Gilles M, Meyer-Lindenberg A et al. Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series. Pharmacopsychiatry 2010 43 33-35
111. Salvadore G, Cornwell B R., Colon-Rosario V et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009 65 289-295
112. Kinsler R, Duman R S. Acute ketamine administration increases VEGF expression in the hippocampus: potenzial role in the rapid antidepressant effects of ketamine. Abstract of Society for Neuroscience Meeting at Washington DC 2008; #56.14
113. Warner-Schmidt J L., Duman R S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007 104 4647-4652 (Pubitemid 47186279)
114. Machado-Vieira R, Yuan P, Brutsche N et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 8 Sep 2009; [Epub ahead of print]
115. Stahl S M. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 2008 69 1673-1674
116. Borza I, Domány G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem 2006 6 687-695
117. Inta D, Trusel M, Riva M A. et al. Differential c-Fos induction by different NMDA receptor antagonists with antidepressant efficacy: potenzial clinical implications. Int J Neuropsychopharmacol 2009 12 1133-1136
118. Preskorn S H., Baker B, Kolluri S et al. An innovative design to establish proof of concept of the antidepressant effects of the NR 2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008 28 631-637
119. Mineur Y S., Picciotto M R., Sanacora G. Antidepressant-like effects of ceftriaxone in male C 57BL/ 6J mice. Biol Psychiatry 2007 61 250-252 (Pubitemid 46072785)
120. Rothstein J D., Patel S, Regan M R. et al. -lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005 433 73-77 (Pubitemid 40101145)
121. Berk M, Copolov D L., Dean O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008 64 468-475